InvestingPro analysis shows the company maintains a strong balance sheet with more cash than debt, though it's currently experiencing accelerated cash burn. Duravyu is EyePoint's sustained release tyrosine kinase inhibitor (TKI) product being developed for wet age-related macular degeneration (wAMD). The company also reported lower operating expenses in its quarterly results. Mizuho expressed continued confidence in EyePoint's position in the competitive wet AMD market, citing three key advantages: robust Phase 2 data supporting Duravyu's potential, a straightforward pivotal Phase 3 clinical development program that better represents real-world use, and a leading position for potential first approval of a TKI-based product for wAMD.